Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 11, 2008, Pages 1209-1216

  Artz, Andrew S ^a,b   Wickrema, Amittha ^a,b   Dinner, Shira ^a   Godley, Lucy A ^a,b   Kocherginsky, Masha ^a   Odenike, Olatoyosi ^a,b   Rich, Elizabeth S ^a,b   Stock, Wendy ^a,b   Ulaszek, Jodie ^a   Larson, Richard A ^a,b   van Besien, Koen ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b University of Chicago   (United States)

Author keywords

CRP; IL 6; Reduced intensity; Toxicity; Transplantation

Indexed keywords

ALEMTUZUMAB; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; MELPHALAN; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; COMORBIDITY; CONTROLLED STUDY; CRYOPRESERVATION; DISEASE SEVERITY; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION COMPLICATION; LENGTH OF STAY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK ASSESSMENT; T CELL DEPLETION; TRANSPLANTATION TOLERANCE;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; C-REACTIVE PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-6; LENGTH OF STAY; LIVER DISEASES; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 53849093452     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.08.004     Document Type: Article

References (51)

1. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 104 (2004) 961-968
2. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104 (2004) 1550-1558
3. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105 (2005) 1810-1814
4. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 19 (2005) 2304-2312
5. Artz A.S., Pollyea D.A., Kocherginsky M., et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 12 (2006) 954-964
6. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
7. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 110 (2007) 4606-4613
8. Gauldie J., Richards C., Harnish D., et al. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 84 (1987) 7251-7255
9. Mantovani G., Madeddu C., Gramignano G., et al. Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients. Oncol Rep 11 (2004) 197-206
10. Penninx B.W., Kritchevsky S.B., Newman A.B., et al. Inflammatory markers and incident mobility limitation in the elderly. J Am Geriatr Soc 52 (2004) 1105-1113
11. Ridker P.M., Hennekens C.H., Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
12. Reuben D.B., Judd-Hamilton L., Harris T.B., et al. The associations between physical activity and inflammatory markers in high-functioning older persons: MacArthur Studies of Successful Aging. J Am Geriatr Soc 51 (2003) 1125-1130
13. Ferrucci L., Harris T.B., Guralnik J.M., et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 47 (1999) 639-646
14. Ridker P.M., Rifai N., Stampfer M.J., et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
15. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107 (2003) 1486-1491
16. Shlipak M.G., Wassel Fyr C.L., Chertow G.M., et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 17 (2006) 254-261
17. Reuben D.B., Cheh A.I., Harris T.B., et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc 50 (2002) 638-644
18. Harris T.B., Ferrucci L., Tracy R.P., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106 (1999) 506-512
19. Ramsey S., Lamb G.W., Aitchison M., et al. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109 (2007) 205-212
20. Crumley A.B., McMillan D.C., McKernan M., et al. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 94 (2006) 1568-1571
21. Schots R., Kaufman L., Van Riet I., et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia 17 (2003) 1150-1156
22. Min C.K., Lee W.Y., Min D.J., et al. The kinetics of circulating cytokines including IL-6, TNF-alpha, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 28 (2001) 935-940
23. Pihusch M., Pihusch R., Fraunberger P., et al. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol 76 (2006) 93-101
24. Fuji S., Kim S.W., Fukuda T., et al. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 14 (2008) 510-517
25. Min C.K., Kim S.Y., Eom K.S., et al. Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse. Bone Marrow Transplant 37 (2006) 493-498
26. van Besien K., Artz A., Smith S., et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23 (2005) 5728-5738
27. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995) 825-828
28. Peto R., and Peto J. Asymptotically efficient rank-invariant test procedures (with discussion). J R Stat Soc A 135 (1972) 185-206
29. Cox D.R. Regression models and life tables. J R Stat. Soc B 34 (1972) 187-220
30. Gray R. cmprsk: Subdistribution Analysis of Competing Risks (2004), R Foundation for Statistical Computing, Vienna, Austria
31. Lunn M., and McNeil D. Applying Cox regression to competing risks. Biometrics 51 (1995) 524-532
32. van Besien K., Artz A., and Stock W. Unrelated donor transplantation over the age of 55: are we merely getting (b)older?. Leukemia 19 (2005) 31-33
33. Yanada M., Emi N., Naoe T., et al. Allogeneic myeloablative transplantation for patients aged 50 years and over. Bone Marrow Transplant 34 (2004) 29-35
34. Rothenburger M., Markewitz A., Lenz T., et al. Detection of acute phase response and infection: the role of procalcitonin and C-reactive protein. Clin Chem Lab Med 37 (1999) 275-279
35. Blijlevens N.M., Donnelly J.P., Meis J.F., et al. Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. Clin Diagn Lab Immunol 7 (2000) 889-892
36. de Bel C., Gerritsen E., de Maaker G., et al. C-reactive protein in the management of children with fever after allogeneic bone marrow transplantation. Infection 19 (1991) 92-96
37. Schots R., Van Riet I., Othman T.B., et al. An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogeneic bone marrow transplantation. Bone Marrow Transplant 30 (2002) 441-446
38. Tegg E.M., Griffiths A.E., Lowenthal R.M., et al. Association between high interleukin-6 levels and adverse outcome after autologous haemopoietic stem cell transplantation. Bone Marrow Transplant 28 (2001) 929-933
39. Zouki C., Beauchamp M., Baron C., et al. Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest 100 (1997) 522-529
40. Cermak J., Key N.S., Bach R.R., et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82 (1993) 513-520
41. Kuo H.K., Bean J.F., Yen C.J., et al. Linking C-reactive protein to late-life disability in the National Health and Nutrition Examination Survey (NHANES) 1999-2002. J Gerontol A Biol Sci Med Sci 61 (2006) 380-387
42. Ravaglia G., Forti P., Maioli F., et al. Peripheral blood markers of inflammation and functional impairment in elderly community-dwellers. Exp Gerontol 39 (2004) 1415-1422
43. Ershler W.B., and Keller E.T. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 51 (2000) 245-270
44. Biasucci L.M., Vitelli A., Liuzzo G., et al. Elevated levels of interleukin-6 in unstable angina. Circulation 94 (1996) 874-877
45. Morley J.J., and Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci 389 (1982) 406-418
46. Pearson T.A., Bazzarre T.L., Daniels S.R., et al. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 107 (2003) 645-651
47. Gruenewald T.L., Seeman T.E., Ryff C.D., et al. Combinations of biomarkers predictive of later life mortality. Proc Natl Acad Sci U S A 103 (2006) 14158-14163
48. Sorror M., Storer B., Sandmaier B.M., et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112 (2008) 1992-2001
49. Guilfoyle R., Demers A., Richardson E., et al. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant centre. Biol Blood Marrow Transplant 14 Suppl 2 (2008) 32
50. Van Besien K., De Lima M., Artz A., et al. Alemtuzumab reduces chronic graft versus host disease (cGVHD) and treatment-related mortality (TRM) after reduced-intensity conditioning for AML and MDS. [abstract]. Blood 110 (2007) 1076
51. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 23 (2005) 9387-9393